Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

New Upgrade:   Dedicated Screeners for Stocks & ETFs

Learn more
Market News Market Pulse Stocks News ETF News Crypto News

Werewolf Therapeutics, Inc.

Contributing Author

Recent Articles by Werewolf Therapeutics, Inc.

Oct-30
Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting HOWL -10.35% GlobeNewswire
Aug-21
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement HOWL +102.57% GlobeNewswire
Jul-31
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates HOWL -29.44% GlobeNewswire
May-07
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates HOWL HOWL +9.68% GlobeNewswire
Mar-27
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates HOWL -9.54% GlobeNewswire
Feb-24
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives HOWL GlobeNewswire
Dec-18
Werewolf Therapeutics Announces Pipeline and Business Updates HOWL -39.57% GlobeNewswire
Nov-07
Werewolf Therapeutics Presents Data Expanding Its PREDATOR Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting HOWL GlobeNewswire
Nov-04
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update HOWL -7.63% GlobeNewswire
Oct-08
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer HOWL GlobeNewswire
Oct-03
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting HOWL +6.77% GlobeNewswire
Sep-02
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference HOWL GlobeNewswire
Aug-14
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update HOWL GlobeNewswire
Jul-09
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit HOWL GlobeNewswire
Jun-12
Werewolf Therapeutics to Participate in the BIO International Convention HOWL GlobeNewswire
May-29
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference HOWL GlobeNewswire
May-20
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 HOWL HOWL -5.26% GlobeNewswire
May-13
Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit HOWL GlobeNewswire
May-08
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update HOWL -5.54% GlobeNewswire
May-05
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting HOWL GlobeNewswire
May-05
Werewolf Therapeutics to Participate in Upcoming Investor Conferences HOWL GlobeNewswire
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)